Condition: Lymphoma, B-Cell · Sponsor: Medolution Ltd.
The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R/R-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.
This description comes directly from the study's public registry record.
Jin Yan, MD · +8618652596381 · jin.yan@teligene.com
Always discuss trial participation with your own doctor first.
| Cancer Hospital, Chinese Academy of Medical Sciences | Beijing, Beijing Municipality, China | Not Yet Recruiting |
| Peking University Third Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality, China | Recruiting |
| West China Hospital，Sichuan University | Chengdu, Sichuan, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04807881